Get the Stockscreener App
4.35
3.12%
-0.14
After Hours:
4.35
Atea Pharmaceuticals Inc stock is traded at $4.35, with a volume of 210.71K.
It is down -3.12% in the last 24 hours and up +6.10% over the past month.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
See More
Previous Close:
$4.49
Open:
$4.49
24h Volume:
210.71K
Relative Volume:
0.60
Market Cap:
$348.12M
Revenue:
$351.37M
Net Income/Loss:
$-169.52M
P/E Ratio:
-2.0483
EPS:
-2.1237
Net Cash Flow:
$-147.86M
1W Performance:
+0.69%
1M Performance:
+6.10%
6M Performance:
+38.10%
1Y Performance:
+37.66%
1-Day Range:
$4.31
$4.53
1-Week Range:
$4.30
$4.585
52-Week Range:
$2.78
$6.45
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Name
Atea Pharmaceuticals Inc
Sector
Industry
Phone
(857) 284-8891
Address
225 FRANKLIN STREET, BOSTON
Compare AVIR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
4.35 | 359.32M | 351.37M | -169.52M | -147.86M | -2.1237 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-10-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-18-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-25-20 | Initiated | Evercore ISI | Outperform |
| Nov-24-20 | Initiated | JP Morgan | Overweight |
| Nov-24-20 | Initiated | Morgan Stanley | Overweight |
| Nov-24-20 | Initiated | William Blair | Outperform |
View All
Atea Pharmaceuticals Inc Stock (AVIR) Latest News
Are medical stocks lagging Atea Pharmaceuticals (AVIR) this year? - MSN
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
Atea Pharmaceuticals (AVIR) Rallies 1.65% as Shares Test Key Resistance Near $4.54Scalping Stock Signals - newsline.com
Atea Pharmaceuticals (AVIR) Declines 3.85% as Shares Approach Key Support LevelPCR Mean Reversion - newsline.com
AVIR Stock Chart | ATEA PHARMACEUTICALS INC (NASDAQ:AVIR) - ChartMill
AVIR SEC FilingsAtea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Atea Pharmaceuticals (AVIR) price target increased by 33.33% to 8.16 - MSN
Atea PharmaceuticalsI'm Optimistic Ahead Of Critical HPV Catalyst (NASDAQ:AVIR) - Seeking Alpha
Atea Pharmaceuticals Q1 earnings call highlights - MSN
Atea Pharmaceuticals Q1 2026 Earnings: Narrower Loss Beats Expectations; Stock Edges HigherFiscal Year Earnings - The Legal Advocate
Atea Pharmaceuticals Rises After Hepatitis C Data; 2026 Readouts Eyed - Bez Kabli
Atea presents hepatitis C drug interaction data at EASL - Investing.com UK
Atea Pharmaceuticals Presents New Drug-Drug Interaction - GlobeNewswire
Atea Pharmaceuticals (AVIR) Holds Steady Near Support Amid Flat Trading SessionPre-Earnings Momentum - newsline.com
Atea Pharmaceuticals (AVIR) Gains 4.25% as Biotech Sentiment Lifts the StockValue Factor - Newser
Spotlight On Atea Pharmaceuticals And 2 Other Prominent Penny Stocks - Yahoo Finance
Atea Pharmaceuticals (AVIR) Edges Higher Amid Renewed Investor InterestBuffered ETF - Newser
Atea Pharmaceuticals (AVIR) Gains 4.25% as Stock Tests Key Resistance LevelActive ETF Flow - The Legal Advocate
Atea Pharmaceuticals (AVIR) Shows Modest Uptick, Holding Above Key SupportCommunity Pattern Alerts - Newser
Atea Pharmaceuticals director Polly Murphy buys $25,446 in stock By Investing.com - Investing.com Canada
Atea Pharmaceuticals director Polly Murphy buys $25,446 in stock - Investing.com
Atea Pharmaceuticals (AVIR) director buys 6,100 shares of stock - Stock Titan
Atea (AVIR) director adds 6,100 shares in open-market purchase - Stock Titan
Atea Pharma (AVIR) Stock: Up +1.69%, Key Resistance at $4.42 2026-05-19Community Exit Signals - Newser
Here's Why We're Watching Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation - Yahoo Finance
Down 25% in 4 weeks, here's why Atea Pharmaceuticals (AVIR) looks ripe for a turnaround - MSN
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reveals stock plunge after EPS miss By Investing.com - Investing.com South Africa
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reveals stock plunge after EPS miss - Investing.com Nigeria
Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Cuts Target Price to $4.1 - Moomoo
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround - Yahoo Finance
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline - Sahm
We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully - Moomoo
Atea Pharmaceuticals Sets Up Catalyst-Rich 2026 Earnings Call - TipRanks
Atea Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2026 Earnings Call Transcript - Insider Monkey
Atea Pharmaceuticals Announces Three Accepted Abstracts for Presentation at EASL Congress 2026 - Quiver Quantitative
Atea Pharmaceuticals to Present Three Abstracts at EASL - GlobeNewswire
Atea anticipates Phase III C-BEYOND midyear and C-FORWARD year-end readouts while projecting cash runway through 2027 - MSN
New hepatitis C and E drug data headed to EASL 2026 congress - Stock Titan
Atea Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:AVIR) 2026-05-12 - Seeking Alpha
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reports slight EPS miss, stock dips - Investing.com Nigeria
Atea Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript - Benzinga
[10-Q] Atea Pharmaceuticals, Inc. Quarterly Earnings Report - Stock Titan
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results - TradingView
Atea Pharmaceuticals reports Q1 2026 net loss $45.4M, cash & marketable securities $256.0M - TradingView
Atea Pharmaceuticals (NASDAQ:AVIR) Q1 Loss Narrows as HCV and HEV Pipeline Catalysts Loom - ChartMill
Atea Pharmaceuticals Inc Stock (AVIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):